Get the Stockscreener App
0.36
5.78%
-0.0221
After Hours:
.35
-0.01
-2.78%
Athira Pharma Inc stock is traded at $0.36, with a volume of 619.80K.
It is down -5.78% in the last 24 hours and down -6.44% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.3821
Open:
$0.36
24h Volume:
619.80K
Relative Volume:
3.23
Market Cap:
$14.20M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1165
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-7.76%
1M Performance:
-6.44%
6M Performance:
+9.76%
1Y Performance:
-29.38%
1-Day Range:
$0.3538
$0.38
1-Week Range:
$0.3525
$0.40
52-Week Range:
$0.2195
$0.8264
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.36 | 15.03M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
What Fibonacci levels say about Athira Pharma Inc. reboundJuly 2025 Final Week & Proven Capital Preservation Tips - Newser
What does recent volatility data suggest for Athira Pharma Inc.Market Rally & AI Enhanced Execution Alerts - Newser
Using data filters to optimize entry into Athira Pharma Inc.July 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Is Athira Pharma Inc. stock reversal real or fakeJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - Newser
What MACD and RSI say about Athira Pharma Inc.2025 EndofYear Setup & AI Driven Stock Movement Reports - Newser
Chart based analysis of Athira Pharma Inc. trends2025 Market Overview & Smart Allocation Stock Reports - Newser
Is it too late to sell Athira Pharma Inc.Volume Spike & Verified Chart Pattern Signals - Newser
Using economic indicators to assess Athira Pharma Inc. potentialWeekly Profit Report & Community Driven Trade Alerts - Newser
Will Athira Pharma Inc. benefit from macro trendsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
Does Athira Pharma Inc. show high probability of reboundQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - Newser
Can volume confirm reversal in Athira Pharma Inc.Portfolio Risk Summary & Verified Short-Term Trading Plans - Newser
Live market analysis of Athira Pharma Inc.July 2025 Fed Impact & High Yield Equity Trading Tips - Newser
Using data models to predict Athira Pharma Inc. stock movementJuly 2025 Review & Reliable Momentum Entry Alerts - Newser
Applying Wyckoff theory to Athira Pharma Inc. stockMarket Performance Recap & Community Consensus Stock Picks - Newser
Visualizing Athira Pharma Inc. stock with heatmaps2025 Top Gainers & Smart Swing Trading Techniques - Newser
Athira Pharma Announces 10-for-1 Reverse Stock Split - Nasdaq
Athira pharma announces 10-for-1 reverse stock split - MSN
Athira Pharma announces reverse stock split - MarketScreener
Athira Pharma Announces Reverse Stock Split - GlobeNewswire
10-for-1 Reverse Split: Athira Pharma Restructures Shares to Maintain Nasdaq Listing, Boost Appeal - Stock Titan
Relative strength of Athira Pharma Inc. in sector analysisJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
What to expect from Athira Pharma Inc. in the next 30 daysJuly 2025 News Drivers & Accurate Entry and Exit Point Alerts - Newser
How to read the order book for Athira Pharma Inc.2025 Biggest Moves & Real-Time Volume Triggers - Newser
What data driven models say about Athira Pharma Inc.’s futureEarnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Price momentum metrics for Athira Pharma Inc. explained2025 Stock Rankings & AI Enhanced Execution Alerts - Newser
Analyzing net buyer seller activity in Athira Pharma IncJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
What’s the recovery path for long term holders of Athira Pharma Inc.July 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Using AI based signals to follow Athira Pharma Inc.July 2025 Outlook & Stock Portfolio Risk Management - Newser
Is Athira Pharma Inc. stock bottoming outJuly 2025 Intraday Action & Short-Term Trading Alerts - Newser
Is Athira Pharma Inc. a candidate for recovery play2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
Applying Elliott Wave Theory to Athira Pharma Inc.2025 Technical Patterns & Smart Investment Allocation Insights - Newser
Has Athira Pharma Inc. found a price floorMarket Growth Report & Technical Analysis for Trade Confirmation - Newser
Smart tools for monitoring Athira Pharma Inc.’s price actionJuly 2025 Price Swings & Expert Curated Trade Setups - Newser
What moving averages say about Athira Pharma Inc.Earnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
applying wyckoff theory to athira pharma inc. stockQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):